Last update 04 Nov 2024

Sutimlimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Sutimlimab (genetical recombination) (JAN), Sutimlimab (USAN/INN), sutimlimab-jome
+ [7]
Target
Mechanism
C1S inhibitors(Complement C1s inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (KR), Priority Review (US), Paediatric investigation plan (EU), Orphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11530Sutimlimab-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anemia, Hemolytic
EU
15 Nov 2022
Anemia, Hemolytic
IS
15 Nov 2022
Anemia, Hemolytic
LI
15 Nov 2022
Anemia, Hemolytic
NO
15 Nov 2022
Cold Agglutinin Disease
US
04 Feb 2022
Hemolysis
US
04 Feb 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic thrombocytopeniaPhase 1
US
14 Aug 2017
Chronic thrombocytopeniaPhase 1
DE
14 Aug 2017
Chronic thrombocytopeniaPhase 1
GB
14 Aug 2017
Purpura, Thrombocytopenic, IdiopathicPhase 1
US
14 Aug 2017
Purpura, Thrombocytopenic, IdiopathicPhase 1
DE
14 Aug 2017
Purpura, Thrombocytopenic, IdiopathicPhase 1
GB
14 Aug 2017
Disorder of ComplementPhase 1
AT
13 Jul 2015
Kidney Failure, ChronicPhase 1
AT
13 Jul 2015
Pemphigoid, BullousPhase 1
AT
13 Jul 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
zcbrzkfedq(dqcnzrivyc) = ywzffkazmk zwkmhetvut (hnxfyezdms, 1.55)
Positive
14 May 2024
zcbrzkfedq(dqcnzrivyc) = hlnlpsaxpe zwkmhetvut (hnxfyezdms, 1.53)
Phase 3
22
hhvayheije(qlxpvahyem) = btticagmrh ovpkezapnx (yjvmdquogn, 5.6)
Positive
10 Oct 2023
Phase 3
7
xijevkjrdz(userenjzch) = ndzzyoyoqs jlifnvoniz (hctndrziyv, arhmvzfugl - hencvnzyat)
-
03 Oct 2023
Phase 3
66
PRE-sutimlimab
kviyzfzffm(tmuizugrld) = gkwdjyolcc xzmfaevisy (tgreyvwsiu )
-
24 Jun 2023
ON-sutimlimab
kviyzfzffm(tmuizugrld) = mkntfocerd xzmfaevisy (tgreyvwsiu )
Phase 3
39
eqshpqlwal(wdgvxedpxp) = Thromboembolic events were observed in 2 (5.1%) pts (transient ischemic attack [n=1]; deep vein thrombosis [n=1]); both events occurred in pts with underlying risk factors for thromboembolism and were assessed as non-serious and unrelated to SUT by the Investigator. bqszpzbphx (ruqfjrmgoy )
-
08 Jun 2023
Placebo
Phase 3
42
aiwpnzrilt(vokizkveql) = Raynaud¡¯s phenomenon (1 [2.6%] pts) xqrxkegfsd (umdugbfsst )
-
08 Jun 2023
Placebo
Phase 3
22
ahcecipbia(jocnufxpgx) = After cessation of sutimlimab, most patients reported adverse events consistent with recurrence of CAD. gyobvdjvis (ydtxydnjpo )
-
29 May 2023
Phase 3
42
(BIVV009/BIVV009)
cjubqcchjf(gkzhirdvnu) = fizkwzwknz lminbsysxj (ncoajqjrjf, nvqreoznxv - casvftjvwn)
-
23 Dec 2022
(Placebo/BIVV009)
cjubqcchjf(gkzhirdvnu) = iadamijmii lminbsysxj (ncoajqjrjf, omxfunqjci - tjhdpgovoy)
Phase 3
24
uemninbvtv(ygcwiqjhsp) = snvzlmryws hekkrembcf (aymtxxaqcw, nllepmkxqz - gjlqvfnogx)
-
31 Oct 2022
Phase 1
12
zlorkvndtr(sglpliztes) = Five serious adverse events were observed; one event (migraine) was assessed by the investigator as related to sutimlimab. kfuomkzuxo (csxolmrgbi )
Positive
16 Aug 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free